What is Elicio Therapeutics Financial Strength?
Elicio Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Elicio Therapeutics did not have earnings to cover the interest expense.
As of today, Elicio Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Elicio Therapeutics's Financial Strength
For the Biotechnology subindustry, Elicio Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's Financial Strength falls into.
Elicio Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Elicio Therapeutics's Interest Expense for the
months ended in Dec. 2023 was $-0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-9.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.01 Mil.
Elicio Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is
| Elicio Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Elicio Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Elicio Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (Elicio Therapeutics) Business Description
Traded in Other Exchanges
Address
One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Executives
| Yekaterina Chudnovsky |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Robert R Ruffolo |
director |
|
| Peter Demuth |
officer: Chief Scientific Officer |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Assaf Segal |
director |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Annette Matthies |
officer: Chief Business Officer |
ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139 |
| Robert Connelly |
director, officer: CEO, President and Director |
1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
| Julian Adams |
director |
C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116 |
| Christopher Haqq |
officer: See Remarks |
C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Carol Gail Ashe |
director |
C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
| Brian Piekos |
officer: Chief Financial Officer |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Karen J Wilson |
director |
C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
| Gilbert S Omenn |
director |
AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Gregory S Curhan |
officer: See Remarks |
600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
| Itzhak Goldberg |
officer: See Remarks |
51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553 |
| John F. Neylan |
officer: See Remarks |
750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Elicio Therapeutics (Elicio Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELTX has been successfully added to your